The options paper acknowledged that the need for multiple submissions could delay funded patient access for several years. Yet it effectively accepted them as an intractable feature of our HTA systems. …
The process does not cause delays, it promotes them for the best medicines
August 5, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 October
October 17, 2025 - - Podcast -
New partnership aims to strengthen local cell and gene manufacturing capability
October 16, 2025 - - Australian Biotech -
Vertex announces New Zealand registration of next-generation cystic fibrosis treatment
October 16, 2025 - - Latest News -
Lilly’s oral GLP-1 therapy delivers strong results in late-stage diabetes trials
October 16, 2025 - - Latest News -
NDIS participant numbers and spending continue growth trajectory in latest quarterly data
October 15, 2025 - - Other Health -
Key Pharmaceuticals builds on a 40-year legacy to support frontline health
October 15, 2025 - - Latest News